Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Intense Endocrine Therapy for High Risk and Locally Advanced Prostate Cancer
NCT05406999Phase 2Recruiting
- Sponsor
- Nanjing Drum-Tower Hospital
- Start
- Feb 2020
- Primary completion
- Dec 2026
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label trial of Abiraterone Acetate Tablets (I), enzalutamide, apalutamide, darolutamide and rezvilutamide in prostate cancer (PCa) (8 arms), sponsored by Nanjing Drum-Tower Hospital. Primary endpoints: Pathologic response rate at 3 years and Biochemical Progression-Free Survival at 3 years. Started Feb 2020; status: recruiting.
02
Drugs
Abiraterone Acetate Tablets (I)enzalutamideapalutamidedarolutamiderezvilutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT05406999.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05406999.